

**INTERNATIONAL TRADE COMMISSION**

**Sunshine Act Meeting**

**Agency Holding the Meeting:**  
International Trade Commission.

**TIME AND DATE:** February 23, 2004, at 11 a.m.

**PLACE:** Room 101, 500 E Street, SW., Washington, DC 20436. Telephone: (202) 205-2000.

**STATUS:** Open to the public.

**MATTERS TO BE CONSIDERED:**

1. Agenda for future meetings: none.
2. Minutes.
3. Ratification list.
4. Inv. No. 731-TA-1069

(Preliminary) (Outboard Engines from Japan)—briefing and vote. (The Commission is currently scheduled to transmit its determination to the Secretary of Commerce on or before February 23, 2004; Commissioners' opinions are currently scheduled to be transmitted to the Secretary of Commerce on or before March 1, 2004.)

5. Outstanding action jackets: none.

In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission:

Issued: February 12, 2004.

**Marilyn R. Abbott,**

*Secretary to the Commission.*

[FR Doc. 04-3549 Filed 2-12-04; 4:50 pm]

**BILLING CODE 7020-02-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on October 23, 2003, Applied Science Labs, Division of Alltech Associates Inc., 2701 Carolean Industrial Drive, P.O. Box 440, State College, Pennsylvania 16801, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic class of controlled substances listed below:

Drug	Schedule
2, 5-dimethoxy-4-(n)-propylthiophenethylaminie (2C-T-7) (7348).	I
Alpha-methyltryptamine (AMT) (7432).	I

Drug	Schedule
5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT) (7439).	I

The firm plans to manufacture small quantities of the listed controlled substances for reference standards.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Division Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than April 19, 2004.

Dated: February 4, 2004.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control.*

[FR Doc. 04-3475 Filed 2-17-04; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to section 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on October 29, 2003, Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50619 made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below.

Drug	Schedule
Amphetamine (1100) .....	II
Methylphenidate (1724) .....	II
Dextropropoxphene (9273) .....	II

The firm plans to manufacture bulk controlled substances for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice,

Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than April 19, 2004.

Dated: February 4, 2004.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04-3481 Filed 2-17-04; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Registration**

By notices dated March 11, 2003, and published in the **Federal Register** on April 2, 2003 (68 FR 16088), dated April 3, 2003, and published in the **Federal Register** on April 15, 2003 (68 FR 18262), dated June 20, 2003, and published in the **Federal Register** on July 8, 2003 (68 FR 40686), and dated October 7, 2003, and published in the **Federal Register** on October 29, 2003 (68 FR 61698), Cody Laboratories, Inc., 331 33rd Street, Cody, Wyoming 82414, made application by letters and by renewals to the Drug Enforcement Administration for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Dihydromorphine (9145) .....	I
Amphetamine (1100) .....	II
Methamphetamine (1105) .....	II
Amobarbital (2125) .....	II
Pentobarbital (2270) .....	II
Secobarbital (2315) .....	II
Phenylacetone (8501) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Diphenoxylate (9170) .....	II
Meperidine (9230) .....	II
Oxymorphone (9652) .....	II
Sufentanil (9740) .....	II
Fentanyl (9801) .....	II

On December 30, 2003, the firm requested that their registration be modified to reflect an address change to 601 Yellowstone Drive, Cody, Wyoming 82414. That modification was effected on January 8, 2004.

The firm plans to manufacture bulk materials for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the registration of Cody Laboratories, Inc. to manufacture the listed controlled substances is consistent with the public

interest at this time. DEA has investigated Cody Laboratories, Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed is granted.

Dated: February 4, 2004.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04-3482 Filed 2-17-04; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 25, 2003, Irix Pharmaceuticals, Inc., 101 Technology Place, Florence, South Carolina 29501, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of methylphenidate (1724), a basic class of controlled substance listed in Schedule II.

The firm plans to manufacture methylphenidate for sale to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than April 19, 2004.

Dated: February 4, 2004.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04-3480 Filed 2-17-04; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 25, 2003, Johnson Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Tetrahydrocannabinols (7370) .....	I
Difenoxin (9168) .....	I
Propiram (9649) .....	I
Amphetamine (1100) .....	II
Methylphenidate (1724) .....	II
Codeine (9050) .....	II
Oxycodone (9143) .....	II
Hydrocodone (9193) .....	II
Meperidine (9230) .....	II
Morphine (9300) .....	II
Thebaine (9333) .....	II
Alfentanil (9737) .....	II
Sufentanil (9740) .....	II
Fentanyl (9801) .....	II

The firm plans to manufacture the listed controlled substances in bulk to supply to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than April 19, 2004.

Dated: February 4, 2004.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04-3476 Filed 2-17-04; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importation of Controlled Substances; Notice of Application**

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(1)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Section 1301.34 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on December 9, 2003, Lipomed, Inc., One Broadway, Cambridge, Massachusetts 02142, made application by renewal and letter to the Drug Enforcement Administration to be registered as an importer of the basic classes of controlled substances listed below:

Drug	Schedule
Cathinone (1235) .....	I
Methaqualone (2565) .....	I
Gamma-Hydroxybutyric Acid (2010) .....	I
Lysergic acid diethylamide (7315) .....	I
Marihuana (7360) .....	I
Tetrahydrocannabinols (7370) ....	I
Mescaline (7381) .....	I
3,4,5-Trimethoxyamphetamine (7390) .....	I
4-Bromo-2-5-diethoxyamphetamine (7391) .....	I
4-Methyl-2,5-diethoxyamphetamine (7395) .....	I
2,5-Dimethoxyamphetamine (7396) .....	I
2,5-Dimethoxy-4-ethylamphetamine (7399) .....	I
3,4-Methylenedioxyamphetamine (7400) .....	I
3,4-Methylenedioxy-N-ethylamphetamine (7404) .....	I
3,4-Methylenedioxymethamphetamine (7405) .....	I
Psilocybin (7437) .....	I
Psilocyn (7438) .....	I
Acetyldihydrocodeine (9051) .....	I
Dihydromorphine (9145) .....	I
Heroin (9200) .....	I
Tilidine (9750) .....	I
Amphetamine (1100) .....	II
Methamphetamine (1105) .....	II
Amobarbital (2125) .....	II
Secobarbital (2315) .....	II
Phencyclidine (7471) .....	II
Cocaine (9041) .....	II
Codeine (9050) .....	II